

GLOBAL MED TECHNOLOGIES INC

Form 4

April 01, 2010

**FORM 4**
**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**HAEMONETICS CORP**

2. Issuer Name **and** Ticker or Trading  
Symbol  
**GLOBAL MED TECHNOLOGIES  
INC [GLOB]**

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
**400 WOOD ROAD,**  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
**03/25/2010**

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

**BRAINTREE, MA 02184**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_\_X\_\_ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/25/2010		J <sup>(1)(2)</sup>		103,700	A	\$ 1.22	31,532,430 <sup>(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	03/26/2010		J <sup>(1)(2)</sup>		827,303	A	\$ 1.22	32,359,733 <sup>(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	03/29/2010		J <sup>(1)(2)</sup>		1,590,800	A	\$ 1.22	33,950,533 <sup>(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	03/30/2010		J <sup>(1)(2)</sup>		41,000	A	\$ 1.22	33,991,533 <sup>(3)</sup>	I	See Footnote

Common Stock	03/31/2010	J <sup>(1)(2)</sup>	406,519	A	\$ 1.22	34,398,052 <sup>(3)</sup>	I	(4) See Footnote (4)
Common Stock	04/01/2010	J <sup>(1)(5)</sup>	1,036,776	A	\$ 1.22	35,434,828 <sup>(3)</sup>	I	(4) See Footnote (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HAEMONETICS CORP 400 WOOD ROAD BRAINTREE, MA 02184		X		
Atlas Acquisition Corp. C/O HAEMONETICS CORPORATION 400 WOOD ROAD BRAINTREE, MA 02184		X		

## Signatures

HAEMONETICS CORPORATION /s/ Christopher J. Lindop, its Chief Financial Officer

04/01/2010

\_\_Signature of Reporting Person

Date

ATLAS ACQUISITION CORP. /s/ Christopher J. Lindop, its President

04/01/2010

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) In accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 31, 2010, by and among Haemonetics Corporation, a Massachusetts corporation ("Haemonetics"), Atlas Acquisition Corp., a Colorado corporation and a direct wholly-owned subsidiary of Haemonetics, and Global Med Technologies, Inc., a Colorado corporation ("Global Med"), Atlas Acquisition Corp. commenced a cash tender offer (the "Offer") to purchase all outstanding shares of Global Med Common Stock, \$0.01 par value per share (the "Common Shares"), and Series A Convertible Preferred Stock, \$0.01 par value per share ("Preferred Shares"), subject to the terms and conditions set forth in the Offer to Purchase, dated February 19, 2010, as amended (the "Offer to Purchase"), included as an exhibit to the Tender Offer Statement on Schedule TO filed by Haemonetics and Atlas Acquisition Corp. with the Securities and Exchange Commission on February 19, 2010.

(2) The reported Common Shares were purchased during the subsequent offering period contemplated by the Merger Agreement and the Offer to Purchase.

(3) Excludes 5,500,000 Common Shares issuable upon conversion of 3,960 Preferred Shares of the Issuer, which Preferred Shares are subject to "blocker" provisions prohibiting the holder from converting the Preferred Shares to the extent that such conversion would result in the holder becoming the beneficial owner of more than 9.99% of the outstanding Common Shares.

(4) The reported securities are owned indirectly by Haemonetics and directly by Atlas Acquisition Corp.

(5) The reported Common Shares were purchased upon exercise of the "top-up option" contemplated by the Merger Agreement and the Offer to Purchase.

### Remarks:

This report is filed jointly by Haemonetics Corporation and Atlas Acquisition Corp.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.